The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy

Area of Science:

• Oncology
• Cell Biology
• Cancer Research

Background:

• Vessel co-option (VCO) is a non-angiogenic tumor vascularization mechanism.
• VCO enables tumors to utilize pre-existing vasculature for nutrients and invasion.
• It is linked to poor prognosis and resistance to anti-angiogenic therapies.

Purpose of the Study:

• To review the cellular and molecular mechanisms underlying VCO.
• To explore potential therapeutic strategies targeting VCO.
• To address the lack of current treatments inhibiting VCO.

Main Methods:

• Literature review of recent studies on VCO.
• Analysis of molecular and cellular processes in VCO.
• Identification of therapeutic targets and strategies.

Main Results:

• Co-opted vessels exhibit a quiescent phenotype, unlike angiogenic vessels.
• Cancer cells adhere to basement membranes via integrins, showing mesenchymal traits.
• The tumor microenvironment, including ECM and immune cells, influences VCO.

Conclusions:

• VCO is a critical factor in tumor progression and therapy resistance.
• Targeting VCO mechanisms offers a potential strategy to overcome anti-angiogenic resistance.
• Further research into VCO inhibition is needed for novel therapeutic development.